Oppenheimer Asset Management Inc. Buys Shares of 47,664 Core Laboratories Inc. $CLB

Oppenheimer Asset Management Inc. bought a new position in Core Laboratories Inc. (NYSE:CLB) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 47,664 shares of the oil and gas company’s stock, valued at approximately $555,000. Oppenheimer Asset Management Inc. owned approximately 0.10% of Core Laboratories at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of CLB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Core Laboratories by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock valued at $418,000 after purchasing an additional 1,170 shares in the last quarter. American Century Companies Inc. increased its holdings in Core Laboratories by 14.3% in the 2nd quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company’s stock worth $1,533,000 after buying an additional 16,677 shares in the last quarter. Quantbot Technologies LP increased its holdings in Core Laboratories by 343.7% in the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock worth $202,000 after buying an additional 13,571 shares in the last quarter. Sei Investments Co. purchased a new position in Core Laboratories in the 2nd quarter worth about $231,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Core Laboratories by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after acquiring an additional 1,040 shares during the period. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Insider Buying and Selling at Core Laboratories

In other Core Laboratories news, CEO Lawrence Bruno bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the transaction, the chief executive officer owned 262,438 shares of the company’s stock, valued at $2,829,081.64. This trade represents a 1.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.26% of the stock is currently owned by company insiders.

Core Laboratories Stock Up 1.5%

Shares of CLB stock opened at $12.64 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.12 and a quick ratio of 1.55. Core Laboratories Inc. has a one year low of $9.79 and a one year high of $20.36. The company’s fifty day moving average price is $11.59 and its 200-day moving average price is $14.62. The company has a market capitalization of $579.92 million, a price-to-earnings ratio of 22.57, a PEG ratio of 3.00 and a beta of 1.03.

Core Laboratories (NYSE:CLB) last issued its earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The company had revenue of $124.61 million during the quarter, compared to the consensus estimate of $126.26 million. During the same quarter in the prior year, the firm posted $0.19 EPS. Core Laboratories’s quarterly revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Sell-side analysts expect that Core Laboratories Inc. will post 0.53 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. Core Laboratories’s dividend payout ratio is 7.14%.

Wall Street Analyst Weigh In

CLB has been the topic of a number of recent analyst reports. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Thursday, August 13th. Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Core Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Core Laboratories Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.